Rigaku Analytical Devices Inc

Charles River Laboratories International provides research models and laboratory animal support services, pre-clinical services and clinical services to the biomedical market. The company offers a suite of patented Integrated Clinical Technologies for managing global clinical trials, including customized interactive voice response and web applications, comprehensive clinical trial management systems, and drug safety and pharmacovigilance systems. Its clients include nearly every major pharmaceutical and biotechnology company in the world, as well as leading academic institutions and government research centers. The company s headquarters in Wilmington, Mass., and branch offices located in Europe, Canada and Asia, serve clients in more than 50 countries throughout the world.

Aquilus Pharmaceuticals Inc is a privately held biotechnology company based in Woburn, MA, specializing in the treatment and management of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. They have developed a promising MMP-2 and MMP-9 inhibitor, AQU-118, which has shown efficacy in reducing neuronal damage in animal models of nerve injury. Aquilus believes that ALS is a result of a systemic wide inflammatory process triggered by mis-folding events, leading to the overexpression and production of MMP-9 in motor neurons. Their research suggests that the uncontrollable rise in MMP-9 levels contributes to the breakdown of vital CNS proteins and the activation of inflammatory cytokines, ultimately leading to motor neuron cell death. Aquilus aims to complete all necessary studies by the end of 2022 and begin clinical development of AQU-118 for ALS treatment in 2023.Generated from the website

Organix performs contract research and development for organic and medicinal chemistry and biotechnology applications. The company s capabilities include custom synthesis of organic molecules; optimization of existing synthetic methods; structure activity relationship studies to discover new molecules and optimize lead compounds; joint projects to discover and synthesize new molecular entities designed for specific functions; and characterization of components of complex organic mixtures. Organix is licensed by the United States Drug Enforcement Agency and the Commonwealth of Massachusetts to conduct research and manufacturing processes of controlled substances in schedules one to four. Its staff of scientists has been published in numerous scientific journals. The company was founded in 1986 and is based in Woburn, Mass.